View Older Stories View More Recent Stories

Apr 9, 2018 02:00AM ABIVAX Strengthens Its Management Team with the Appointment of Alexandra Pearce, Ph.D. as Vice President of Regulatory Affairs
Mar 16, 2018 03:30AM ABIVAX: 2017 Full-Year Results and Progress Report
Mar 12, 2018 03:30PM ABIVAX Upcoming Events
Jan 29, 2018 02:00AM ABIVAX Appoints Carol L. Brosgart, M.D. to its Board of Directors
Jan 4, 2018 02:00AM ABIVAX to Initiate Long-Term Extension Study of ABX464 in Patients with Ulcerative Colitis
Dec 21, 2017 02:00AM ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018
Dec 15, 2017 12:00PM ABIVAX Announces Its Financial Calendar for 2018
Dec 15, 2017 02:00AM ABIVAX’s ABX464 Phase IIa Data confirm HIV Reservoir Reduction in Oral Presentation at 8th International Workshop on HIV Persistence During Therapy
Dec 7, 2017 02:00AM ABIVAX to Present in Plenary Session at the 8th International Conference on HIV Persistence During Therapy
Nov 22, 2017 02:00AM ABIVAX to Present at German Equity Forum 2017
Nov 20, 2017 02:00AM Abivax Enrolls First Ulcerative Colitis Patient in New ABX464 Proof-of-Concept Clinical Trial
Oct 30, 2017 03:00AM ABIVAX to Present at BIO-Europe® 2017 – 23rd Annual International Partnering Conference
Oct 12, 2017 02:00AM ABIVAX Presents Novel Data on the Efficacy of Its Immune Enhancer ABX196 in Animal Model of Liver Cancer at the World Vaccine Congress
Oct 5, 2017 02:00AM ABIVAX Expands Scientific Advisory Board with Appointment of Renowned Virologist and Former President of the Pasteur Institute, Prof. Christian Bréchot
Sep 28, 2017 02:00AM ABIVAX Secures an Equity Line Financing with Kepler Cheuvreux
Sep 28, 2017 01:30AM ABIVAX’s ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial
Sep 20, 2017 02:00AM ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis
Sep 18, 2017 02:00AM ABIVAX: First Patient Dosed in Three-Month Cohort of Phase 2a Study of Oral ABX464 in HIV-Suppressed Patients
Sep 11, 2017 01:00PM ABIVAX Presents Full ABX464 Positive Phase 2A Clinical HIV Data at the HIV Cure and Reservoir Symposium
Sep 7, 2017 02:40AM Evotec and ABIVAX Enter into Strategic Collaboration to Develop Novel Antiviral Agents
Sep 7, 2017 01:30AM ABIVAX and Evotec Enter into Strategic Collaboration to Develop Novel Antiviral Agents
Jul 13, 2017 02:00AM ABIVAX to Present Latest Clinical Data on ABX464 at the International Aids Society Conference in Paris, France
Jun 15, 2017 02:00AM Prof. Jamal Tazi, Inventor of ABX464, ABIVAX’s Lead Drug Candidate for Inducing a Functional Cure for HIV, Awarded the CNRS Medal of Innovation 2017
Jun 12, 2017 12:00PM ABIVAX to Receive €390,000 From Bpifrance for the Development of Its Ebola Hyperimmune Candidate
May 11, 2017 03:00PM ABIVAX Announces the Publication of Its 2016 Registration Document and Highlights the Development Stage of Its Portfolio
May 2, 2017 02:00AM First ever evidence of treatment-induced reduction in HIV reservoirs: ABX464, ABIVAX’ lead drug candidate, impacted HIV blood reservoir in a Phase IIa clinical trial (ABX464-004)
May 2, 2017 01:00AM ABIVAX Confirms Trading Resumption
Apr 28, 2017 11:00AM ABIVAX Confirms Trading Suspension
Apr 11, 2017 12:00PM ABIVAX Expands Its Antiviral Portfolio with Compounds Targeting Zika Virus
Apr 4, 2017 12:00PM ABIVAX Initiates Clinical Trial (ABX464-005) to Evaluate the Effect of ABX464 on HIV-Reservoirs in HIV Patients
Feb 23, 2017 02:00AM ABIVAX Has Discovered Novel Antiviral Molecules with Potential for Dengue Virus Treatment
Feb 16, 2017 12:00PM ABIVAX to Participate in RBC Capital Markets Global Healthcare Conference on February 22-23, 2017 in New York City
Feb 2, 2017 12:00PM Phase I Clinical Data of ABX464, ABIVAX’s First-in-Class Anti-HIV Drug, Published in Two Articles in Peer-Reviewed Journals
Jan 9, 2017 12:00PM ABIVAX to Receive €8.4 Million from Bpifrance “Invest in the Future Program” (PIA) for the Development of Innovative Antiviral Drugs
Jan 4, 2017 12:00PM ABIVAX to Present at the Biotech Showcase™ Annual Conference in San Francisco
Dec 19, 2016 12:00PM ABIVAX Announces Its Financial Calendar for 2017
Dec 15, 2016 12:00PM ABIVAX Appoints Didier Blondel as Chief Financial Officer
Dec 8, 2016 12:00PM ABIVAX Reports New Preclinical Data Supporting ABX464 as HIV Functional Cure and Novel Treatment for Inflammatory Diseases at HIV DART Meeting
Dec 6, 2016 12:00PM ABIVAX Provides Update on Clinical Development Program for ABX464 for Functional Cure of Patients with HIV-Infection
Nov 24, 2016 12:00PM ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy
Nov 22, 2016 03:31PM ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy
Nov 16, 2016 12:00PM ABIVAX to Present Phase IIa Clinical Data on ABX464 During NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016
Nov 15, 2016 01:30PM ABIVAX to Present at Upcoming Investors Conferences
Oct 28, 2016 02:30AM ABIVAX to Attend the Jefferies 2016 London Healthcare Conference
Oct 27, 2016 12:00PM ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland
Oct 11, 2016 02:00AM ABIVAX Announces R&D Day at Company’s New Collaborative Laboratory in Montpellier
Oct 4, 2016 02:30AM ABIVAX: Publication of a shareholder newsletter
Sep 20, 2016 12:00PM ABIVAX Announces the Publication of Its 2016 Half-Year Financial Report
Sep 20, 2016 12:00PM ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results
Sep 13, 2016 12:30PM ABIVAX Completes the Second Milestone in CaReNa, a “Strategic Industrial Innovation Project” Supported by Bpifrance
View More Recent Stories View Older Stories